Prurigo nodularis
☆ AI Dermatology — Free Service
I te 2022 Stiftung Warentest hua mai i Tiamana, he iti noa iho te pai o nga kaihoko ki a ModelDerm i nga korero mo te waea rongoa utu.
I te 2022 Stiftung Warentest hua mai i Tiamana, he iti noa iho te pai o nga kaihoko ki a ModelDerm i nga korero mo te waea rongoa utu.
relevance score : -100.0%
ReferencesKo te Prurigo nodularis he mate kiri roa e tohuhia ana e te maha o ngā nodula, ka kitea i runga i ngā ringaringa me ngā waewae. He rerekē te tae o ēnei nodula, mai i te kiko‑kiko ki te māwhero me te tino kikorangi. Ka pā ki ngā tangata ahakoa te pakeke, ā he maha ngā wā e hono ana ki ētahi atu momo kiri e mate ai te mate kiri, pērā i te atopic dermatitis. Ko ngā whiringa māimoatanga ko ngā rongoā antipruritic kaha (potent antipruritics), ngā rongoā immunomodulator (immunomodulators), me ngā rongoā neuromodulator (neuromodulators). Ko te whakahaere i te Prurigo nodularis ko te nuinga o te wā he rongoā mō te wā roa.
Prurigo nodularis is a chronic disorder of the skin that is classically seen as multiple, firm, flesh to pink colored papules, plaques and nodules commonly located on the extensor surfaces of the extremities. The lesions are very pruritic and can occur in any age group. It is commonly associated with another disease such as atopic dermatitis or any dermatoses associated with chronic pruritus. The therapeutic approach is wide-arrayed ranging from treatments that act as - potent antipruritics, immunomodulators, and neuromodulators. Treatment in an established case is prolonged and improving patient compliance with education and counseling is important.
Prurigo nodularis is a chronic disorder of the skin that is classically seen as multiple, firm, flesh to pink colored papules, plaques and nodules commonly located on the extensor surfaces of the extremities. The lesions are very pruritic and can occur in any age group. It is commonly associated with another disease such as atopic dermatitis or any dermatoses associated with chronic pruritus. The therapeutic approach is wide-arrayed ranging from treatments that act as - potent antipruritics, immunomodulators, and neuromodulators. Treatment in an established case is prolonged and improving patient compliance with education and counseling is important.
I te nuinga o te wa ko te maimoatanga ko te whakamahi kirīmi, werohanga steroids ranei ki te waahi kua pa. I roto i nga keehi tino kino, pakeke ranei, ka hiahiatia nga maimoatanga penei i te whakamaarama marama me nga rongoa ka pehia te punaha mate. Ko te Thalidomide me te lenalidomide nga whiringa mo nga keehi kino, engari ka pa mai pea nga paanga kino. Ko nga maimoatanga hou ake (opioid receptor antagonists, neurokinin-1 receptor antagonists) e whakaatu ana i te oati mo te rongoa i te prurigo nodularis me te iti ake o nga paanga taha ki te thalidomide, lenalidomide ranei.
Treatment typically relies on the use of topical or intralesional steroids, though more severe or recalcitrant cases often necessitate the use of phototherapy or systemic immunosuppressives. Thalidomide and lenalidomide can both be used in severe cases; however, their toxicity profile makes them less favorable. Opioid receptor antagonists and neurokinin-1 receptor antagonists represent two novel families of therapeutic agents which may effectively treat PN with a lower toxicity profile than thalidomide or lenalidomide.
Treatment typically relies on the use of topical or intralesional steroids, though more severe or recalcitrant cases often necessitate the use of phototherapy or systemic immunosuppressives. Thalidomide and lenalidomide can both be used in severe cases; however, their toxicity profile makes them less favorable. Opioid receptor antagonists and neurokinin-1 receptor antagonists represent two novel families of therapeutic agents which may effectively treat PN with a lower toxicity profile than thalidomide or lenalidomide.
Ko te Chronic prurigo he mate kiri e tohuhia ana e te patitotanga roa (neke atu i te 6 wiki) , nga whiu kiri e pa ana ki te rakuraku, me te hitori o te rakuraku auau. Kei roto i te neuroinflammation me te fibrosis i roto i te kiri.
Chronic prurigo (CPG) is a neuroinflammatory, fibrotic dermatosis that is defined by the presence of chronic pruritus (itch lasting longer than 6 weeks), scratch-associated pruriginous skin lesions and history of repeated scratching.
Chronic prurigo (CPG) is a neuroinflammatory, fibrotic dermatosis that is defined by the presence of chronic pruritus (itch lasting longer than 6 weeks), scratch-associated pruriginous skin lesions and history of repeated scratching.
Ko te Prurigo nodularis he raruraru kiri roa e tohuhia ana e ngā nodule e pāwhakā. Kaore mātou i te tino mōhio he aha te take, engari ka whai wāhi ngā take pūmautanga me te pūāhua ki te huringa o te pāwhakā. I tēnei wā, kāore he māimoatanga i whakaaetia e te US FDA mō te Prurigo nodularis.
Prurigo nodularis is a long-lasting skin problem marked by itchy nodules. We don't know exactly what causes it, but it seems that immune and nerve issues play a role in the itch-scratch cycle. Right now, there aren't any treatments approved by the US FDA specifically for prurigo nodularis.
Prurigo nodularis is a long-lasting skin problem marked by itchy nodules. We don't know exactly what causes it, but it seems that immune and nerve issues play a role in the itch-scratch cycle. Right now, there aren't any treatments approved by the US FDA specifically for prurigo nodularis.
○ Maimoatanga ― OTC Drugs
Ko te horoi i te wāhi mate ki te hopi kāre e awhina, ka kino ake. Ka awhina pea ngā hinu steroid OTC ki te whakaora i ngā tohu, engari me tono mō etahi wiki kia pai ake ai. Ko te haere tonu ki te tango i ngā antihistamines ka awhina anō hoki ki te whakaora i te pūkū.
#OTC steroid ointment
#OTC antihistamine
○ Maimoatanga
#Intralesional triamcinolone injection